The Centers for Disease Control and Prevention (CDC) Vaccine Adverse Event Reporting System (VAERS), is the primary US government-funded system for reporting adverse vaccine reactions in the U.S. The most recent data shows a total of 1,151,450 reports of adverse events following Covid vaccines were submitted to VAERS between December 14, 2020, and February 25, 2022. A total of 24,827 reports of deaths, an increase of 425 over the last week, and 200,331 reports of serious injuries, including deaths, during the same time period. This is up 4,128 compared with last week. It is widely acknowledged that VAERS vastly under-reports, by a factor of at least 41 and perhaps 100, so the deaths and adverse effects are truly staggering.
“The Centers for Disease Control and Prevention (CDC) today released new data showing a total of 1,151,450 reports of adverse events following COVID vaccines were submitted between Dec. 14, 2020, and Feb. 25, 2022, to the Vaccine Adverse Event Reporting System (VAERS). VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.
The data included a total of 24,827 reports of deaths — an increase of 425 over the previous week — and 200,331 reports of serious injuries, including deaths, during the same time period — up 4,128 compared with the previous week.
Excluding “foreign reports” to VAERS, 774,373 adverse events, including 11,312 deaths and 74,257 serious injuries, were reported in the U.S. between Dec. 14, 2020, and Feb. 25, 2022.
Foreign reports are reports foreign subsidiaries send to U.S. vaccine manufacturers. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product’s labeling, the manufacturer is required to submit the report to VAERS.
Of the 11,312 U.S. deaths reported as of Feb. 25, 18% occurred within 24 hours of vaccination, 22% occurred within 48 hours of vaccination and 60% occurred in people who experienced an onset of symptoms within 48 hours of being vaccinated.
In the U.S., 552 million COVID vaccine doses had been administered as of Feb. 25, including 325 million doses of Pfizer, 208 million doses of Moderna and 18 million doses of Johnson & Johnson (J&J).
Every Friday, VAERS publishes vaccine injury reports received as of a specified date. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed. Historically, VAERS has been shown to report only 1% of actual vaccine adverse events.
U.S. VAERS data from Dec. 14, 2020, to Feb. 25, 2022, for 5- to 11-year-olds show:
8,817 adverse events, including 200 rated as serious and 4 reported deaths.
The most recent death involves an 8-year-old boy (VAERS I.D. 2109625) from Mississippi who died 7 days after his second dose of Pfizer’s COVID vaccine when he was found blue and lifeless at home.
He was taken to the hospital with a full code in process. A pulse was detected several times, but the boy ultimately died in the ICU. It was reported to the doctor who filed the report that the boy died from multisystem inflammatory syndrome. He did not have COVID.
- 17 reportsof myocarditis and pericarditis (heart inflammation).
- 32 reportsof blood clotting disorders.
U.S. VAERS data from Dec. 14, 2020, to Feb. 25, 2022, for 12- to 17-year-olds show:
- 29,797 adverse events, including 1,714 rated as seriousand 39 reported deaths.
The most recent death involves a 13-year-old girl (VAERS I.D. 2115839) from Wisconsin who was severely compromised and received two doses of Pfizer’s COVID vaccine. Although the cause of death wasn’t clear, she appeared to have significant health issues, respiratory distress and heart problems.
- 69 reportsof anaphylaxis among 12- to 17-year-olds where the reaction was life-threatening, required treatment or resulted in death — with 96% of cases
attributed to Pfizer’s vaccine. - 648 reportsof myocarditis and pericarditis with 631 cases attributed to Pfizer’s vaccine.
- 159 reportsof blood clotting disorders, with all cases attributed to Pfizer.
U.S. VAERS data from Dec. 14, 2020, to Feb. 25, 2022, for all age groups combined, show:
- 19% of deaths were related to cardiac disorders.
- 54% of those who died were male, 41% were female and the remaining death reports did not include the gender of the deceased.
- The average ageof death was 72.6.
- As of Feb. 25, 5,176 pregnant womenreported adverse events related to COVID vaccines, including 1,653 reports of miscarriage or premature birth.
- Of the 3,587 cases of Bell’s Palsyreported, 51% were attributed to Pfizer vaccinations, 40% to Moderna and 8% to J&J.
- 853 reports of Guillain-Barré syndrome, with 41% of cases attributed to Pfizer, 30% to Modernaand 28% to J&J.
- 2,339 reportsof anaphylaxis where the reaction was life-threatening, required treatment or resulted in death.
- 1,621 reportsof myocardial infarction.
- 13,320 reportsof blood clotting disorders in the U.S. Of those, 5,946 reports were attributed to Pfizer, 4,744 reports to Moderna and 2,568 reports to J&J.
- 4,060 casesof myocarditis and pericarditis with 2,505 cases attributed to Pfizer, 1,373 cases to Moderna and 172 cases to J&J’s COVID vaccine.
Pfizer vaccine only 12% effective in kids 5 to 11, study says
A study released Monday showed the effectiveness of Pfizer’s COVID vaccine in 5- to 11-year-olds was only 12% after a seven-week period of observation. Yet, the authors of the study still recommended the vaccine for that age group, stating it was protective against severe disease.
They also proposed the recommended dose for 5- to 11-year-olds was too small, suggesting a higher dose might solve the problem.
Some scientists at the CDC and FDA pushed for the data to be made public before an FDA meeting, scheduled for Feb. 15, to review Pfizer’s application for Emergency Use Authorization of a three-dose regimen of its vaccine for infants and children 6 months to 5 years old — but the study’s findings were only made public this week.
The FDA on Feb. 11 abruptly postponed the meeting to review Pfizer’s application for infants and children under 5, stating Pfizer didn’t have enough data on the efficiency of a third dose for that age group.
In an article published March 1, Dr. Madhava Setty, senior science editor at The Defender, examined the data in the study and outlined two flaws in the authors’ conclusions: 1) that the vaccines prevent severe disease in this age group, and 2) that increasing the dose might be appropriate.”